GlassScriptPhysician profile
Laura Mae Given
NPI 1992230262
$2,534.00
in general payments reported to CMS, 2019-2025
21 companies · $1,799 in 2025
The $1,799 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.87 · 2023: $45.86 · 2024: $652 · 2025: $1,799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $467.62 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $390.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $277.62 | 2023-2025 | Airsupra, Farxiga |
| Pfizer INC. | $245.83 | 2023-2025 | |
| Amgen INC. | $207.41 | 2024-2025 | Repatha, Evenity, Otezla |
| Dynavax Technologies Corporation | $147.67 | 2024-2025 | Heplisav-B |
| Lilly USA, LLC | $141.66 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $140.67 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $103.15 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $77.70 | 2024 | |
| Novartis Pharmaceuticals Corporation | $63.92 | 2025 | |
| Boston Scientific Corporation | $51.11 | 2024-2025 | Intracept, Watchman Access System |
| Merck Sharp & Dohme LLC | $41.78 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $30.80 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.13 | 2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.96 | 2025 | Caplyta |
| Abbott Laboratories | $23.44 | 2022 | |
| Dexcom, INC. | $22.89 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $18.96 | 2024 | Rexulti |
| Si-Bone, INC. | $18.46 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Given listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.